Trump Reclassifies Marijuana to Schedule III
Analysis based on 10 articles · First reported Dec 18, 2025 · Last updated Dec 18, 2025
The reclassification of marijuana is expected to significantly reduce the tax burden on the cannabis industry, potentially boosting profitability and investment in the sector. It also opens new avenues for medical research, which could benefit pharmaceutical and healthcare companies involved in cannabis-derived products.
President Donald Trump signed an executive order to reclassify marijuana from a Schedule I to a Schedule III drug, a move that aligns federal policy closer to many states' approaches. This reclassification, which the United States — Drug Enforcement Administration is expected to expedite, will not legalize recreational use nationwide but will change how the drug is regulated and reduce the tax burden on the cannabis industry. The order also calls for expanded research and access to CBD. While Donald Trump received support from some, many United States — Republican Party (United States) senators, led by Ted Budd, opposed the change, arguing it would undermine efforts to 'Make America Great Again' and benefit entities like China. This action follows a similar proposal by Joe Biden's United States — United States Department of Justice. Polling from Gallup indicates growing public support for less restrictive marijuana policies. The United States — Food and Drug Administration has found scientific support for marijuana's medical uses, and a new United States — Medicare program, announced by Mehmet Oz of the United States — Centers for Medicare & Medicaid Services, will allow older adults access to CBD. Opponents like Smart Approaches to Marijuana have vowed to sue if the reclassification proceeds.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard